UPF
11.5.2021 07:02:09 CEST | Business Wire | Press release
World leaders and experts joined more than a million global participants for the launch of “Think Tank 2022” on May 9 KST during the virtual 6th Rally of Hope for the peaceful reunification of the Korean Peninsula.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210510006060/en/
The rally, sponsored by the Universal Peace Federation (UPF), was streamed live from South Korea to 194 nations and translated into 14 languages. Think Tank 2022 is a global multi-sector network of more than 2,000 experts from a wide range of fields—government, business, academia, faith, media, arts and culture—dedicated to the collaborative search for solutions to the world’s most critical challenges.
World-class leaders including the rally’s 12 keynote speakers affirmed and enhanced the concept of Think Tank 2022. “This network will make a difference for peace on the Korean Peninsula through international unity,” said Ban Ki-Moon , former United Nations Secretary-General and chairman of the new initiative. “I applaud Dr. Hak Ja Han Moon, UPF, and the leaders of Think Tank 2022.”
Former European Commission President José Manuel Barroso reminded the audience, that “peace also includes goodwill, trust and justice. The foundation of peace is each human being. The coronavirus taught us the lesson that we have to act and cooperate on a global scale.” “As leaders from around the world who cherish the values of faith, family, democracy and justice under law,” said former U.S. Vice President Mike Pence . “I commend you for coming together at this event to continue to sow the seeds of peace, believing that in time we will reap a harvest of peace that will benefit the people of Korea, the United States and all mankind.”
Born in present-day North Korea, UPF co-founders Dr. Hak Ja Han Moon and her late husband, Rev. Dr. Sun Myung Moon, fled to the south during the Korean War and have devoted their lives to advancing a more peaceful world and reuniting Korea. Think Tank 2022, will spearhead peacebuilding initiatives such as a UN Peace Park on the DMZ; building a Korea-Japan undersea tunnel; boosting Geumgang Mountain tourism development; and helping separated Korean families find their relatives.
“A reunified, denuclearized Korean Peninsula will bring massive peace and prosperity to the peninsula and to the region,” said Mike Pompeo , former U.S. Secretary of State and CIA Director. “Religious freedom is indeed the foundation of all freedoms...with prayer, faith, and commitment to the Lord, peace will follow.”
Many speakers, including former Republic of Korea Prime Minister Chung Sye-Kyun and Cambodian Prime Minister Hun Sen , praised the timeliness of Think Tank 2022 where “international cooperation and solidarity is needed now more than ever,” said Chung.
From Africa, Zanzibar President Dr. Hussein Ali Mwinyi recalled that Africans took part in the Korean War and long for peace and democracy in that region. The peaceful reunification of Korea will lead to “explosive growth,” said renowned American businessman and investor Mr. Jim Rogers . “If trains run through the DMZ and cars run on highways, there will be endless economic development opportunities...benefiting not only the two Koreas, but also China, Russia, Japan and Asia and the whole world.”
Mr. David Beasely , executive director of the United Nations World Food Programme, the world’s largest humanitarian organization and 2020 recipient of the Nobel Peace Prize, said, “This rally is reaching across continents, uniting people all over the world in a spirit of peace, mutual prosperity and public service.”
Governments have failed because they couldn’t go beyond “their bureaucracies, their biases, and their fears,” said Newt Gingrich , former U.S. Speaker of the House of Representatives. Think Tank 2022 offers a new way for people from multiple nations to work together “outside the traditional, formal structures” he said.
“Times of crisis often tend to be the moments of greatest opportunity,” said Mark Esper , former U.S. Secretary of Defense.
"Prof. Sarah Gilbert , co-developer of the Oxford/Astra-Zeneca vaccine said that great advances would result from the challenge of the pandemic, including much speedier development of vaccines to cope with new and mutant viruses. Much greater cooperation between nations was needed to ensure the effective roll-out of the currently available vaccines to nations afflicted by the pandemic as well as greater generosity on the part of richer nations to poorer ones".
The 6th Rally of Hope, part of a digital series started by Dr. Moon in August 2020, has brought together tens of millions of people worldwide who embrace freedom, peace, and unity based on the shared ideals of interdependence, mutual prosperity, and universal values. The Washington Times article on the rally is available here .
Rally of Hope Website (video with highlights of the event): https://www.rallyofhope.eu
View source version on businesswire.com: https://www.businesswire.com/news/home/20210510006060/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom